ホルモン受容体陽性、リンパ節転移陽性の早期乳がんに対し、4～6年間ホルモン療法を受けた閉経後女性におけるレトロゾールによるがん予防効果

基本情報

NCT ID

NCT00553410

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

4,884

治験依頼者名

ETOP IBCSG Partners Foundation

概要

RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known which regimen of letrozole is more effective in postmenopausal women who have received hormone therapy for early-stage breast cancer. PURPOSE: This randomized phase III trial is comparing two different regimens of letrozole in preventing cancer in postmenopausal women who have received 4-6 years of hormone therapy for hormone receptor-positive, lymph node-positive, early-stage breast cancer.

対象疾患

介入

依頼者（Sponsor）

実施施設 (7)